Biomarin Pharmaceutical (BMRN) Cash & Current Investments (2009 - 2026)

Biomarin Pharmaceutical (BMRN) has 18 years of Cash & Current Investments data on file, last reported at $2.2 billion in Q1 2026.

• Quarterly Cash & Current Investments rose 74.67% year-over-year to $2.2 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.2 billion (up 74.67% YoY) and the FY2025 annual result came in at $1.6 billion, up 37.17% from the prior year.
• Cash & Current Investments grew to $2.2 billion in Q1 2026, from $1.6 billion in the prior quarter.
• In the past five years, Cash & Current Investments ranged from a high of $2.2 billion in Q1 2026 to a low of $930.4 million in Q3 2024.
• A 5-year average of $1.3 billion and a median of $1.2 billion in 2023 frame the typical range for Cash & Current Investments.
• Annual changes were most pronounced in 2024 — Cash & Current Investments retreated 17.36% — and 2026, when it jumped 74.67%.
• Tracing BMRN's Cash & Current Investments over 5 years: stood at $1.3 billion in 2022, then retreated by 16.86% to $1.1 billion in 2023, then advanced by 5.95% to $1.1 billion in 2024, then soared by 37.17% to $1.6 billion in 2025, then jumped by 42.41% to $2.2 billion in 2026.
• The last three Cash & Current Investments figures came in at $2.2 billion (Q1 2026), $1.6 billion (Q4 2025), and $1.5 billion (Q3 2025), per Business Quant data.